Capsular contracture, the most common complication in breast implant surgery, is primarily driven by bacterial biofilm formation. Risk is influenced by surgical factors such as incision choice, implant placement, and sterility. Textured implants do not reduce contracture and may increase complications, including breast implant–associated anaplastic large cell lymphoma. Evidence-based strategies—most notably the 14 point plan, betadine-based antimicrobial irrigations, meticulous surgical technique, and structured postoperative care—have reduced contracture rates from up to 50% historically to under 1% in modern practice. Comprehensive management with capsulectomy, site change, and adjuncts further optimizes long-term outcomes and patient satisfaction.
Key points
-
•
Capsular contracture is bacteria-driven complication and can be minimized with high level technique.
-
•
The 14 point plan, betadine-based antimicrobial irrigations, meticulous intraoperative sterility, and careful incision/pocket selection have lowered contracture rates from 50% to less than 1%.
-
•
When contracture occurs, total capsulectomy with site change and implant exchange offers the lowest recurrence; adjuncts such as poly-4-hydroxybutyrate scaffolds improve outcomes in high-risk revisions.
Abbreviations
| ADM | acellular dermal matrix |
| BIA-ALCL | breast implant–associated anaplastic large cell lymphoma |
| P4HB | poly-4-hydroxybutyrate |
| SSI | surgical site infection |
Introduction
Breast implant surgery remains one of the most frequently performed operations in plastic surgery worldwide with estimated 70 million breast implants currently placed. Since the original breast implants developed in 1962, capsular contracture remains the most common complication in both esthetic and reconstructive breast surgery. The pathogenesis of capsular contracture is now firmly established as primarily bacteria-driven, with subclinical microbial contamination of the implant surface triggering a chronic inflammatory response and fibrotic capsule formation. ,
This article synthesizes evidence-based strategies for minimizing bacterial contamination and improving outcomes in breast implant surgery. We review pertinent steps in perioperative optimization, intraoperative technique (14 point plan), and structured postoperative care. Implementation of these evidence-based techniques has reduced capsular contracture rates from historical levels of 50% to less than 1%. ,,,,,,,,,
Pathogenesis and risk factors
Mechanisms of Biofilm Formation
The central mechanism underlying capsular contracture is the formation of a bacterial (planktonic and/or biofilm) on the implant surface, most commonly involving Staphylococcus epidermidis , Cutibacterium (Propionibacterium) acnes , and Escherichia coli . , As early as 24 hours, adherent bacteria can develop biofilm, making them resistant to host immune defenses and systemic antibiotics. A sufficient bacterial load leads to persistent, low-grade inflammation and progressive periprosthetic fibrosis. ,,
Complete sterilization of the implant pocket is not achievable; however, the key concept is to reduce bacterial burden below the threshold at which pathologic host responses are triggered. When the threshold is exceeded, abnormal host responses such as capsular contracture can occur.
Patient and Surgical Risk Factors
Several factors influence the risk for capsular contracture and implant-related complications. Surgical factors include subglandular implant placement, periareolar incision, development of postoperative hematoma or seroma, and inadequate perioperative sterility. ,,
Implant surface characteristics, particularly texturing, were initially believed to offer a protective benefit against capsular contracture; however, this assumption was largely a misinterpretation of early experience with polyurethane-coated implants. In the late 1980s, polyurethane devices demonstrated reduced capsular contracture rates, but this effect was due to unique biochemical interactions and physical adherence properties of polyurethane, not simply the presence of a textured surface. Many surgeons at the time incorrectly attributed the lower contracture rates to the “fuzzy texture” itself, leading to the widespread adoption of other textured implants under the belief that any degree of surface roughness would provide a similar advantage. Subsequent studies, particularly those performed during the anatomic breast implant investigational device exemption (IDE) clinical trial era, were confounded by significant advances in surgical technique and sterility protocols, making it difficult to isolate any independent benefit of texture. When critically reviewing the literature, there is no consistent evidence that textured devices reduce capsular contracture compared to smooth implants. In fact, due to their increased surface area, textured implants provide a more favorable environment for bacterial adhesion and biofilm formation; in controlled studies, capsular contracture rates have sometimes been even higher with textured devices. More recently, the association of textured implants with the rare but serious complication of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) has further challenged the notion that texturing confers a net benefit. ,,
Evidence-based protocols for sterility
Preoperative Optimization
Effective prevention begins with rigorous patient optimization. Modifiable risk factors such as smoking, obesity, and poor glycemic control should be addressed prior to surgery, as perioperative hyperglycemia (target 110–150 mg/dL) is associated with increased surgical site infection (SSI) risk. The Infectious Diseases Society of America recommends a single preoperative dose of intravenous antibiotic with good gram-positive coverage (eg, cefazolin 2 g IV within 60 minutes of incision), with alternatives such as clindamycin or vancomycin for β-lactam-allergic patients. Preoperative bathing with an antiseptic agent is advised for all patients, with additional mupirocin/chlorhexidine decolonization for high-risk cases, as recommended by the Centers for Disease Control and Prevention. ,,
Intraoperative Sterility: The 14 Point Plan
The intraoperative phase is critical for minimizing contamination. The 14 point plan, developed by Adams and Deva, synthesizes evidence-based steps to reduce bacterial load at every stage. ,,, Key elements ( Table 1 ) include avoidance of periareolar incisions, use of nipple shields, atraumatic dissection, meticulous hemostasis, pocket irrigation with proven antimicrobial solutions, minimization of skin-implant contact, glove, and instrument changes prior to implant handling. These steps have been validated in multiple large clinical series with capsular contracture rates under 2%, and as low as 0.1% in single-surgeon, long-term follow-up. ,
Table 1
Evidence-based 14 point intraoperative protocol for breast implant surgery
| Step | Best Practice |
|---|---|
| 1 | Use intravenous antibiotic prophylaxis at the time of anesthetic induction |
| 2 | Avoid periareolar/transaxillary incisions; these have been shown in both laboratory and clinical studies to lead to a higher rate of contracture |
| 3 | Use nipple shields to prevent spillage of bacteria into the pocket |
| 4 | Perform careful atraumatic dissection to minimize devascularized tissue |
| 5 | Meticulous prospective hemostasis |
| 6 | Avoid dissection into the breast parenchyma |
| 7 | Use of a dual-plane pocket |
| 8 | Perform pocket irrigation with betadine triple-antibiotic solution, non–betadine triple-antibiotic, or 50% (1:1 dilution) or more concentrated povidone-iodine. |
| 9 | Steps to minimize skin contamination (eg, wipe/prep skin, barrier, sleeve). |
| 10 | Minimize implant open time and replacement of implant or sizers. |
| 11 | Change surgical gloves before handling and use new or cleaned instruments and drapes. |
| 12 | Avoid routine drains in augmentation (potential entry site for bacteria). |
| 13 | Use a layered closure. |
| 14 | Use antibiotic prophylaxis to cover subsequent procedures that breach skin or mucosa. |
Antimicrobial irrigations
Meticulous antimicrobial breast pocket irrigation and preparation of the skin around the incision are fundamental components of infection prevention protocols in breast surgery. While passive measures such as minimizing bacterial exposure and employing physical barriers play a crucial role in reducing contamination risk, these strategies primarily function by limiting contact with potential pathogens. In contrast, antimicrobial irrigation directly eradicates bacteria and thereby provides an active reduction in microbial load. Among the various solutions studied, povidone-iodine has demonstrated the highest efficacy. Landmark studies have recommended either a 50% betadine solution (prepared as 5% povidone–iodine by diluting stock betadine [10 povidone-iodine] 1:1 with saline) or the betadine triple solution (50% betadine, 1 g cefazolin, 80 mg gentamicin in 500 mL normal saline). The latter emerged in the late 1990s and early 2000s in response to concerns, later shown to be unfounded, that povidone-iodine might weaken implant shell elastomers. Over the past two decades, extensive data has disproven this claim, confirming that povidone-iodine is safe for implants and remains a key element in modern infection prevention strategies. The FDA’s reversal of its previous ban against povidone-iodine use in breast implant procedures has further solidified its role.
Based on more than two decades of experience, our preferred approach to breast pocket irrigation relies on betadine-containing solutions. Key principles of this protocol are as follows: We have routinely utilized a betadine Triple solution to minimize any potential adverse effects of povidone–iodine on wound healing. This solution should be prepared at the time of surgery by a knowledgeable operating room nurse. More recently it has become apparent that most surgeons do not have the operating room setup to reliably formulate betadine Triple and therefore our current recommendation is for surgeons to use 50% betadine to keep the process simple and efficacious. Implants should be immersed in this solution for a minimum of 5 minutes prior to insertion, and the contact time of the irrigation within the breast pocket should be maximized to achieve optimal antimicrobial efficacy.
For certain implant devices, this represents an off-label use; therefore, disclosure in the informed consent process is standard. Over the past 20 years, our patients have uniformly accepted the use of betadine when informed of its benefits in reducing postoperative complications and the need for reoperation.
For patients with a cephalosporin or aminoglycoside allergy, we employ a 50% betadine solution (10% povidone–iodine diluted 1:1 with saline). In rare cases of true betadine allergy, we substitute with non–betadine triple-antibiotic solution (50,000 units bacitracin, 1 g cefazolin + 80 mg gentamicin in 500 cc normal saline without povidone–iodine).
Several misconceptions surrounding povidone–iodine continue to circulate. The following points reflect the current evidence:
-
a.
Betadine does not require drying to be effective.
-
b.
There are no documented cases of bacterial resistance to betadine.
-
c.
Extraluminal betadine does not compromise the integrity of the silicone elastomer implant shell.
-
d.
The statement “betadine is not sterile” is a misconception. Betadine does not intrinsically harbor bacteria. The persistent myth to the contrary arose from historical practices of reusing multidose stock bottles and from a manufacturing contaminant identified more than 30 years ago and subsequently corrected. Sterile preparations of povidone–iodine are commercially available, including betadine skin-prep kits. While the exterior of the bottle is not sterile, the contents are manufactured under sterile conditions and do not support bacterial growth. In our laboratory, we have never cultured bacterial growth from povidone–iodine solution (definition of sterile), and it continues to stand as the gold standard among antiseptics, demonstrating broad-spectrum efficacy with no known resistance.
-
e.
Another misconception occasionally encountered is the suggestion that antibiotic-based breast pocket irrigations contribute to the development of bacterial resistance. This assertion is not supported by the available evidence. The mechanisms driving resistance with systemic antibiotic therapy differ fundamentally from those involved in a single, localized intraoperative application. In contrast to systemic exposure, properly prepared local antimicrobial irrigations have been shown to achieve higher bacterial kill rates within the surgical field, enhance wound angiogenesis, and demonstrate a markedly lower likelihood of fostering resistant organisms.
Surgical technique: incision and pocket selection
The choice of incision and pocket location has a measurable impact on sterility and complication rates. Large-scale studies demonstrate that periareolar incisions are associated with a higher risk of infection and contracture compared to inframammary incisions, with a relative risk of 1.77 for major adverse events and a significantly higher risk of SSI. ,, Subpectoral (submuscular) placement is consistently associated with lower contracture and infection rates than subglandular placement, due to increased vascularity and immune surveillance. ,,
Surgical management of established capsular contracture
Indications and Grading
Surgical intervention is indicated for Baker grade III/IV capsular contracture, characterized by pain, distortion, and functional impairment. Nonsurgical options, such as leukotriene inhibitors (montelukast and zafirlukast), may provide transient symptomatic relief in early stage contracture but do not address the underlying biofilm-mediated pathology and carry risks of hepatotoxicity. , The mainstay of management is surgical, with the goals of eradicating the biofilm, restoring breast esthetics, and minimizing recurrence.
Capsulectomy, Site Change, and Implant Exchange
Total capsulectomy, involving complete removal of the fibrotic capsule, is preferred over partial capsulectomy or capsulotomy, as it is associated with significantly lower recurrence rates (11% vs 46% for partial capsulectomy). ,, Site change, typically from subglandular to subpectoral or neosubpectoral pocket, further reduces recurrence by isolating the new implant from the previously contaminated pocket. , Implant exchange is critical to avoid reintroducing a contaminated device; smooth silicone gel implants are favored, and textured implants are generally avoided due to BIA-ALCL risk. ,
Adjuncts: Acellular Dermal Matrix and Scaffolds
Related posts:
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
